-
1 month ago | 
nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more
AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.
-
1 month ago | 
nature.com | Aqeeb ur Rehman |Moazzam Shahzad |Faiz Anwer |Joseph McGuirk |Mohamad Mohty |Nausheen Ahmed | +1 more
AbstractMeasurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists’ perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received.
-
1 month ago | 
nature.com | Utkarsh Goel |James Davis |William Wesson |Sandra Mazzoni |Mikhaila Rice |Faiz Anwer
The Endothelial Activation and Stress Index (EASIX) score [lactate dehydrogenase (LDH) (U/L) x creatinine (Cr) (mg/dL)/platelet count (109/L)] is a marker of endothelial dysfunction and was initially developed to predict overall survival (OS) after allogeneic hematopoietic cell transplantation [1].
-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 1, 2024 | 
casereports.bmj.com | Ahmad Safdar |Faiz Anwer
DiscussionAmyloidosis involves deposition of toxic protein fibrils that eventually lead to organ dysfunction.1 15 forms of systemic amyloidosis are known, but the most encountered types in clinical practice are amyloid light chain (AL), amyloid A (AA), mutant/hereditary and wild-type amyloid transthyretin (mATTR and wtATTR, respectively).
-
Nov 28, 2024 | 
onlinelibrary.wiley.com | Ludovic Saba |Raymond L. Comenzo |Jack Khouri |Faiz Anwer
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ejh14347-sup-0001-SupinfoS1.docxWord 2007 document , 64.5 KB Data S1. Supporting Information. ejh14347-sup-0002-SupinfoS2.docxWord 2007 document , 19.1 KB Data S2. Supporting Information. References 1 and , “How I Treat AL Amyloidosis,” Blood 139, no. 19 (2022): 2918–2930.
-
Aug 23, 2024 | 
mdpi.com | Barry Paul |Faiz Anwer |Shahzad Raza |Aytaj Mammadzadeh
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Aug 22, 2024 | 
nature.com | Hamlet Gasoyan |Faiz Anwer |Nicholas J. Casacchia |Ming Wang |Michael Halpern
AbstractThis retrospective cohort study used Taussig Cancer Center’s Myeloma Patient Registry to identify adults with multiple myeloma diagnosed between January 2017-December 2021. Electronic health records data captured time from diagnosis to initial prescription fill for oral antimyeloma medications and initiation of facility administered or oral antimyeloma treatment.
-
May 30, 2024 | 
nature.com | Danai Dima |James Davis |Hussein Awada |Faiz Anwer |Shahzad Raza |Zahra Mahmoudjafari | +2 more
AbstractThe presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) chimeric antigen receptor (CAR) T-cell therapy and had active extraosseous EMD before the infusion. Data were retrospectively collected from patients at three US institutions with the intent to receive SOC CAR T.
